Ocuphire Pharma to Present in the BIO CEO & Investor Conference
By Dr. Matthew Watson
FARMINGTON HILLS, Mich., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that George Magrath, M.D. M.B.A, M.S. CEO of Ocuphire, will be presenting a company overview at the BIO CEO & Investor Conference being held February 26-27 2024 in New York City. Company management will also be participating in one-on-one meetings throughout the conference.
More here:
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual…
By Dr. Matthew Watson
REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), is presenting results from three preclinical studies evaluating briquilimab, at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, being held February 23-26 in Washington, D.C. One study will be featured in an oral presentation and two studies in poster presentations.
Read more from the original source:
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual...
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
By Dr. Matthew Watson
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”)
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
By Dr. Matthew Watson
EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business.
Follow this link:
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
Curia Appoints Steve Lavezoli as Vice President, Biologics
By Dr. Matthew Watson
The rest is here:
Curia Appoints Steve Lavezoli as Vice President, Biologics
Tilray Medical Applauds German Bundestag and Landmark Passage of Medical Cannabis Act in Germany
By Dr. Matthew Watson
New Medical Cannabis Act in Germany Provides Easier Access to Medical Cannabis for Patients Through the MedCanG New Medical Cannabis Act in Germany Provides Easier Access to Medical Cannabis for Patients Through the MedCanG
See original here:
Tilray Medical Applauds German Bundestag and Landmark Passage of Medical Cannabis Act in Germany
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
By Dr. Matthew Watson
Originally posted here:
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
Starton Therapeutics to Present at BIO CEO & Investor Conference 2024
By Dr. Matthew Watson
PARAMUS, N.J., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, today announced that Pedro Lichtinger, Chairman and Chief Executive Officer of Starton Therapeutics, will present and host one-on-one meetings at the BIO CEO & Investor Conference being held in New York City, February 26-27, 2024. Details for the event are as follows:
See the original post:
Starton Therapeutics to Present at BIO CEO & Investor Conference 2024
Celularity Announces 1-for-10 Reverse Stock Split
By Dr. Matthew Watson
FLORHAM PARK, N.J., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Celularity, Inc. (Nasdaq: CELU; CELUW) (“Celularity”), a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced that its Board of Directors has approved a 1-for-10 reverse stock split of its Class A common stock, to be effective at 5:00 p.m. Eastern Standard Time, Wednesday, February 28, 2024. Celularity’s Class A common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on Thursday, February 29, 2024, under the current trading symbol, “CELU.” The reverse stock split was approved by Celularity’s stockholders on February 22, 2024, and is intended to increase the per share trading price of its Class A common stock to enable Celularity to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
Visit link:
Celularity Announces 1-for-10 Reverse Stock Split
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
By Dr. Matthew Watson
Company Announcement
Follow this link:
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free…
By Dr. Matthew Watson
REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. In 2023, Humira was one of the highest-grossing pharmaceutical products in the world, with sales in the U.S. of nearly $12.2 billion[1]. Teva is Alvotech’s strategic partner for the exclusive commercialization of SIMLANDI in the United States.
See the original post:
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free...
New approaches to live-track the production of different types of blood cells in mice – Medical Xpress
By daniellenierenberg
New approaches to live-track the production of different types of blood cells in mice Medical Xpress
View original post here:
New approaches to live-track the production of different types of blood cells in mice - Medical Xpress
Orca Bio Presents Promising Data on Orca-T in Two Oral Presentations at the 2024 Tandem Meetings of ASTCT and … – Yahoo Finance
By daniellenierenberg
Orca Bio Presents Promising Data on Orca-T in Two Oral Presentations at the 2024 Tandem Meetings of ASTCT and ... Yahoo Finance
AJMC in the Press, February 23, 2024 – AJMC.com Managed Markets Network
By daniellenierenberg
AJMC in the Press, February 23, 2024 AJMC.com Managed Markets Network
Read more:
AJMC in the Press, February 23, 2024 - AJMC.com Managed Markets Network
Expanding the Horizons of Cell and Gene Therapy – RegMedNet
By daniellenierenberg
Expanding the Horizons of Cell and Gene Therapy RegMedNet
Read the original:
Expanding the Horizons of Cell and Gene Therapy - RegMedNet
If Other Treatments Aren’t Working — Stem Cell Transplant May Be A Good Option In CLL – SurvivorNet
By daniellenierenberg
If Other Treatments Aren't Working -- Stem Cell Transplant May Be A Good Option In CLL SurvivorNet
Continued here:
If Other Treatments Aren't Working -- Stem Cell Transplant May Be A Good Option In CLL - SurvivorNet
The strangers who saved each others lives – BBC
By daniellenierenberg
The strangers who saved each others lives BBC
View original post here:
The strangers who saved each others lives - BBC
Moving Forward: Stem Cells in the Treatment of Spinal Cord Injuries – Corporate Wellness Magazine
By daniellenierenberg
Moving Forward: Stem Cells in the Treatment of Spinal Cord Injuries Corporate Wellness Magazine
Read more here:
Moving Forward: Stem Cells in the Treatment of Spinal Cord Injuries - Corporate Wellness Magazine
Statement of Renovaro Inc
By Dr. Matthew Watson
LOS ANGELES, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The following is a statement by Renovaro (Nasdaq: RENB) in response to Hindenburg's recent opinion piece:
Go here to see the original:
Statement of Renovaro Inc